Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.4 HKD | +3.15% | -6.11% | -19.71% |
07-01 | Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note | MT |
06-26 | Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.41 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.71% | 15.22B | - | ||
+15.58% | 122B | B+ | ||
+16.60% | 113B | B+ | ||
+17.55% | 26.22B | B | ||
-24.33% | 19.01B | B+ | ||
-19.14% | 15.71B | A- | ||
-46.81% | 14.72B | A- | ||
+58.78% | 14.58B | C+ | ||
+4.91% | 13.84B | C+ | ||
+100.06% | 10.4B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BGNE Stock
- 6160 Stock
- Ratings BeiGene, Ltd.